WCM Investment Management
BEAM icon

WCM Investment Management’s Beam Therapeutics BEAM Stock Holding History

WCM Investment Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-78,157
Closed -$4.48M – 204
2022
Q1 		$4.48M Buy
78,157
+7,578
+11% +$497K 0.01% 151
2021
Q4 		$5.62M Buy
+70,579
New +$6.04M 0.01% 152

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

WCM Investment Management's BEAM Position: Q2 2022 in Review

WCM Investment Management sold out of Beam Therapeutics (BEAM) in Q2 2022, closing a stake of 78,157 shares — an estimated $4.48M sold.

WCM Investment Management first reported a position in BEAM in Q4 2021 and held it in 2 quarters. The position peaked at $5.62M in Q4 2021. 205 funds tracked by Wall St. Rank hold BEAM as of Q2 2022.

  • WCM Investment Management reported no remaining Beam Therapeutics position as of Q2 2022 after selling out during the quarter.
  • WCM Investment Management sold 78,157 Beam Therapeutics shares in Q2 2022, an estimated $4.48M.
  • WCM Investment Management first reported a position in Beam Therapeutics in Q4 2021 and held it in 2 quarters.
  • WCM Investment Management's Beam Therapeutics position peaked at $5.62M in Q4 2021.
  • 205 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2022.

Based on WCM Investment Management's 13F filing for Q2 2022, filed 9 Aug 2022.